Association of Serum Lipids with Hepatic Steatosis, Stage of Liver Fibrosis and Viral Load in Chronic Hepatitis C

Valkov, Ivan; Ivanova, Radina; Alexiev, A.; Antonov, Krasimir; Mateva, Lyudmila

doi:10.7860/jcdr/2017/28609.10459

Cited by 12 publications

(16 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although new and efficient drugs that can safely cure hepatitis C with high rates of sustained virological response have been developed, fibrosis still progresses in some patients with a further risk of cirrhosis and HCC development, mainly in those with advanced fibrosis . Recently, liver steatosis has been described as an additional risk factor for fibrosis progression and HCC development in patients with and without hepatitis C . Hepatic steatosis is defined as excessive fat accumulation in the liver.…”

Section: Introductionmentioning

confidence: 99%

Prevalence and predictive factors of moderate/severe liver steatosis in chronic hepatitis C (CHC) infected patients evaluated with controlled attenuation parameter (CAP)

Cardoso

Perez

Figueiredo-Mendes

et al. 2018

Journal of Viral Hepatitis

View full text Add to dashboard Cite

A novel controlled attenuation parameter (CAP) using FibroScan has been developed for assessment of liver steatosis. The aim was to evaluate the frequency and associated factors for moderate/severe steatosis evaluated by CAP in CHC patients submitted to transient elastography (TE) by FibroScan . CHC patients underwent TE with CAP evaluation. The classification of steatosis was defined as: CAP < 222 dB/m = S0; CAP ≥ 222 dB/m and <233dB/m = S1; ≥233 dB/m < 290dB/m = S2 and >= 290 dB/m = S3. The prevalence of moderate/severe steatosis (CAP ≥ S2) and the related independent factors were identified by a logistic regression analysis. A significance level of 5% was adopted. 1104 CHC patients, 85% genotype-1 were included (mean age 55 ± 11 years; 46% male, mean BMI 25 ± 4 Kg/m ). Systemic arterial hypertension and type 2 diabetes mellitus prevalences were 39% and 17%, respectively. Liver stiffness measurement ≥ 9.5 kPa was observed in 39% of patients and steatosis was identified in 50% (S1 = 7%, S2 = 28% and S3 = 15%). The variables independently associated with moderate/severe steatosis were: male gender (OR=1.35; P = .037; 95% CI:1.01-1.81); systemic arterial hypertension (OR=1.57; P = .002; 95% CI:1.17-2.10) and BMI (OR=1.17; P < .01;95% CI:1.12-1.22). In conclusion, when CAP was adopted as a tool to detect steatosis, genotype 1 CHC patients presented a high prevalence of moderate/advanced steatosis. In these patients, liver steatosis was associated mostly to metabolic factors (arterial hypertension and high BMI).

show abstract

Section: Introductionmentioning

confidence: 99%

Prevalence and predictive factors of moderate/severe liver steatosis in chronic hepatitis C (CHC) infected patients evaluated with controlled attenuation parameter (CAP)

Cardoso

Perez

Figueiredo-Mendes

et al. 2018

Journal of Viral Hepatitis

View full text Add to dashboard Cite

show abstract

“…In addition, quantitative analysis of serum lipid levels of liver and fat tissues was not conducted. There are several evidences that serum lipid levels such as TG are associated with liver fat or other fat tissues (Huang et al., 2015; Valkov, Ivanova, Alexiev, Antonov, & Mateva, 2017). Thus, in‐depth experiments with more lipid parameters and analysis for the association of serum lipid levels and fat tissues should be conducted in the further study.…”

Section: Discussionmentioning

confidence: 99%

Section: F I G U R Ementioning

confidence: 99%

Comparative study of the effects of diosmin and diosmetin on fat accumulation, dyslipidemia, and glucose intolerance in mice fed a high‐fat high‐sucrose diet

Chung

Kim

Choi

et al. 2020

Food Science & Nutrition

View full text Add to dashboard Cite

show abstract

“…Disease progression is affected by viral factors that interact with the host's immune and metabolic pathways. [25] However, the validity of the use of serum lipids for assessment of CHC severity needs further investigation. In this study, we found that patients with CHC who had higher cholesterol levels had an increased risk of NAFL.…”

Section: Discussionmentioning

confidence: 99%

Chronic hepatitis C virus infection

Xu¹,

Wang

Gao³

2019

Medicine

View full text Add to dashboard Cite

We investigated associations between inflammatory marker levels and hepatitis C virus (HCV)-related compensated liver cirrhosis risk in patients with chronic hepatitis C (CHC) infection in China. We used a case-control design and data from the records of 110 Chinese patients with CHC and cirrhosis for the study; 458 CHC patients who did not have a diagnosis of cirrhosis were matched to the case group by age and sex characteristics. We also investigated fatty liver disease risk factors. The group of patients with CHC infection and cirrhosis had lower platelet-to-lymphocyte ratio (PLR) values (60.63 [44.09, 89.31]) compared with the control group patients (80.24 [57.85, 111.08]). The results indicated that the group of patients with cirrhosis had higher 4-factor fibrosis index and aspartate aminotransferase (AST)-to-platelet ratio index (APRI) values compared with the group of patients with CHC-only (1.66 [0.98, 2.60] vs 0.71 [0.45, 1.17], respectively; P < .001 and 2.12 [0.97, 4.25] vs 0.99 [0.51, 2.01], respectively; P < .001). Compared with the control group, the AST/alanine aminotransferase ratio (AAR) values in the group of patients with cirrhosis were significantly higher (P < .001). Logistic regression analysis that included model adjustment for demographic characteristics and other factors that could affect cirrhosis risk revealed that greater 1/PLR values were associated with an increased odds of having cirrhosis (adjusted odds ratio [AOR], 95% confidence interval [CI] 0.991 [0.985–0.996]); APRI and AAR values were also independent predictors of the presence of compensated cirrhosis. We found that compared with the patients with CHC-only, the triglyceride, cholesterol, and low-density lipoprotein cholesterol levels in the patients with both CHC and fatty liver disease were significantly higher. The multivariate analysis of the risk of fatty liver development in patients with CHC infection found that cholesterol level was a statistically significant risk factor (AOR [95% CI] 1.380 [1.089–1.750], P = .008). Increased 1/PLR, APRI, and AAR values were associated with increased risks for development of cirrhosis in this population of Chinese patients with CHC infection. Higher cholesterol levels increased the risk of development of fatty liver disease in patients with CHC.

show abstract

Association of Serum Lipids with Hepatic Steatosis, Stage of Liver Fibrosis and Viral Load in Chronic Hepatitis C

Cited by 12 publications

References 28 publications

Prevalence and predictive factors of moderate/severe liver steatosis in chronic hepatitis C (CHC) infected patients evaluated with controlled attenuation parameter (CAP)

Prevalence and predictive factors of moderate/severe liver steatosis in chronic hepatitis C (CHC) infected patients evaluated with controlled attenuation parameter (CAP)

Comparative study of the effects of diosmin and diosmetin on fat accumulation, dyslipidemia, and glucose intolerance in mice fed a high‐fat high‐sucrose diet

Chronic hepatitis C virus infection

Contact Info

Product

Resources

About